계명대학교 의학도서관 Repository

Long-Term Safety and Efficacy of Pitavastatin in Patients With Acute Myocardial Infarction (from the Livalo Acute Myocardial Infarction Study [LAMIS])

Metadata Downloads
Author(s)
Soon Yong SuhSeung-Woon RhaTae Hoon AhnEak Kyun ShinCheol Ung ChoiDong Joo OhJang-Ho BaeSeung-Ho HurKyung Ho YoonSeok-Kyu OhJong Hyun KimSang Wook KimIn Ho ChaeKee-Sik KimYoung Joon HongMyung Ho Jeong
Keimyung Author(s)
Hur, Seung Ho
Department
Dept. of Internal Medicine (내과학)
Journal Title
American Journal of Cardiology
Issued Date
2011
Volume
108
Issue
11
Abstract
Pitavastatin is a potent lipophilic statin and may play an important role in acute myocardial
infarction (AMI) but there have been limited data on the safety and efficacy of
pitavastatin in AMI. This study consisted of 1,039 consecutive patients with AMI (74.0%
men, mean age 61.4 12.6 years) who presented in 10 major percutaneous coronary
intervention centers in Korea from February 2007 through September 2009. Pitavastatin 2
mg/day was routinely administered in patients with AMI from time of presentation. We
investigated changes of lipid profiles, biochemical markers, adverse events, and clinical
outcomes up to 12 months. During the study 318 events overall occurred in 220 patients
(21.2%) who reported >1 treatment emergent adverse event, although 20 events in 14
patients (1.4%) were treatment-related adverse events. Low-density lipoprotein (LDL)
cholesterol percent change was 25.6% and LDL cholesterol target attainment was 70.5%
at 12-month follow-up. Levels of creatinine phosphokinase, serum glutamic oxaloacetic
transaminase, glutamic pyruvic transaminase, and high-sensitivity C-reactive protein decreased
significantly during the first 1 month of pitavastatin treatment and were sustained
to 12-month follow-up. Major adverse cardiac events occurred in 66 patients (7.3%).
All-cause deaths occurred in 32 patients (3.5%) including 19 (2.1%) cardiac deaths and
recurrent MIs occurred in 14 (1.6%) and target lesion revascularizations in 42 (4.7%). In
conclusion, administration of pitavastatin 2 mg/day in patients with AMI showed 70.5%
LDL cholesterol target attainment with good tolerance and was associated with favorable
clinical outcomes up to 12 months. © 2011 Elsevier Inc. All rights reserved. (Am J
Cardiol 2011;108:1530 –1535)
Keimyung Author(s)(Kor)
허승호
Publisher
School of Medicine
Citation
Soon Yong Suh et al. (2011). Long-Term Safety and Efficacy of Pitavastatin in Patients With Acute Myocardial Infarction (from the Livalo Acute Myocardial Infarction Study [LAMIS]). American Journal of Cardiology, 108(11), 1530–1535. doi: 10.1016/j.amjcard.2011.07.009
Type
Article
ISSN
0002-9149
Source
https://linkinghub.elsevier.com/retrieve/pii/S0002914911022879
DOI
10.1016/j.amjcard.2011.07.009
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/34892
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.